Correction
The authors [1] note that the standard errors in Table 3 (Table 1 here) are actually standard deviations. The reference to standard errors in the footnote has now been edited accordingly.
This is a Correction article on http://www.biomedcentral.com/1741-7015/11/43.
References
Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Medicine. 2013, 11: 43-10.1186/1741-7015-11-43.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/11/193/prepub
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at 10.1186/1741-7015-11-43
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Bailey, C.J., Gross, J.L., Hennicken, D. et al. Erratum to: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11, 193 (2013). https://doi.org/10.1186/1741-7015-11-193
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/1741-7015-11-193